Orthocell Limited (OCC.AX)
AUD 1.58
(-1.25%)
AUD 1.58
(-1.25%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -7.18 Million AUD | -14.93% |
| 2023 | -6.24 Million AUD | 31.39% |
| 2022 | -9.1 Million AUD | -0.77% |
| 2021 | -9.03 Million AUD | -46.92% |
| 2020 | -6.15 Million AUD | -5.11% |
| 2019 | -5.85 Million AUD | -1.65% |
| 2018 | -5.75 Million AUD | -37.82% |
| 2017 | -4.17 Million AUD | -10.37% |
| 2016 | -3.78 Million AUD | -1.13% |
| 2015 | -3.74 Million AUD | -71.51% |
| 2014 | -2.18 Million AUD | -64.9% |
| 2013 | -1.32 Million AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 FY | -7.18 Million AUD | -14.93% |
| 2024 Q2 | -5.23 Million AUD | 0.0% |
| 2024 Q4 | -1.95 Million AUD | 0.0% |
| 2023 FY | -6.24 Million AUD | 31.39% |
| 2023 Q2 | -4.05 Million AUD | 0.0% |
| 2023 Q4 | -2.19 Million AUD | 0.0% |
| 2022 Q2 | -4.65 Million AUD | 0.0% |
| 2022 Q4 | -4.45 Million AUD | 0.0% |
| 2022 FY | -9.1 Million AUD | -0.77% |
| 2021 FY | -9.03 Million AUD | -46.92% |
| 2021 Q4 | -4.64 Million AUD | 0.0% |
| 2021 Q2 | -4.39 Million AUD | 0.0% |
| 2020 FY | -6.15 Million AUD | -5.11% |
| 2020 Q4 | -4.06 Million AUD | 0.0% |
| 2020 Q2 | -2.08 Million AUD | 0.0% |
| 2019 FY | -5.85 Million AUD | -1.65% |
| 2019 Q4 | -4.44 Million AUD | 0.0% |
| 2019 Q2 | -1.4 Million AUD | 0.0% |
| 2018 Q2 | -943.27 Thousand AUD | 0.0% |
| 2018 FY | -5.75 Million AUD | -37.82% |
| 2018 Q4 | -4.81 Million AUD | 0.0% |
| 2017 FY | -4.17 Million AUD | -10.37% |
| 2017 Q2 | -2.84 Million AUD | 0.0% |
| 2017 Q4 | -1.32 Million AUD | 0.0% |
| 2016 Q2 | -2.34 Million AUD | 0.0% |
| 2016 Q4 | -1.43 Million AUD | 0.0% |
| 2016 FY | -3.78 Million AUD | -1.13% |
| 2015 Q2 | -2.74 Million AUD | 0.0% |
| 2015 Q4 | -999.15 Thousand AUD | 0.0% |
| 2015 FY | -3.74 Million AUD | -71.51% |
| 2014 FY | -2.18 Million AUD | -64.9% |
| 2014 Q4 | -1.84 Million AUD | 0.0% |
| 2014 Q2 | -339.26 Thousand AUD | 0.0% |
| 2013 FY | -1.32 Million AUD | 0.0% |
| 2013 Q3 | - AUD | 100.0% |
| 2013 Q4 | -1.11 Million AUD | 0.0% |
| 2013 Q2 | -212.32 Thousand AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AdAlta Limited | -5.38 Million AUD | -33.444% |
| Acrux Limited | -5.8 Million AUD | -23.81% |
| Amplia Therapeutics Limited | -4.5 Million AUD | -59.455% |
| Biome Australia Limited | -1.67 Million AUD | -329.946% |
| BTC Health Limited | 1.05 Million AUD | 780.475% |
| Chimeric Therapeutics Limited | -12.52 Million AUD | 42.689% |
| CSL Limited | 2.64 Billion AUD | 100.272% |
| Clarity Pharmaceuticals Ltd | -42.32 Million AUD | 83.034% |
| Clinuvel Pharmaceuticals Limited | 35.63 Million AUD | 120.151% |
| Noxopharm Limited | -3.57 Million AUD | -100.691% |
| PharmAust Limited | -9.03 Million AUD | 20.497% |
| Proteomics International Laboratories Limited | -6.37 Million AUD | -12.621% |
| Prescient Therapeutics Limited | -8.23 Million AUD | 12.832% |
| PYC Therapeutics Limited | -37.72 Million AUD | 80.965% |
| Race Oncology Limited | -13.81 Million AUD | 48.037% |
| Starpharma Holdings Limited | -8.16 Million AUD | 12.052% |
| EZZ Life Science Holdings Limited | 6.96 Million AUD | 203.108% |
| Botanix Pharmaceuticals Limited | -13.86 Million AUD | 48.226% |
| Memphasys Limited | -4.44 Million AUD | -61.66% |
| Nyrada Inc. | -1.38 Million AUD | -418.022% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -394.815% |
| Telix Pharmaceuticals Limited | 5.21 Million AUD | 237.804% |
| Bio-Gene Technology Limited | -2.4 Million AUD | -198.067% |
| Zelira Therapeutics Limited | -36.56 Million AUD | 80.363% |
| Patrys Limited | -3.53 Million AUD | -102.901% |
| Dimerix Limited | -17.07 Million AUD | 57.945% |
| Neuren Pharmaceuticals Limited | 157.08 Million AUD | 104.572% |
| Imugene Limited | -149.68 Million AUD | 95.202% |
| Cynata Therapeutics Limited | -9.74 Million AUD | 26.309% |
| Immutep Limited | -39.89 Million AUD | 82.001% |
| Arovella Therapeutics Limited | -8.74 Million AUD | 17.895% |
| Alterity Therapeutics Limited | -19.12 Million AUD | 62.449% |
| Nanollose Limited | -1.15 Million AUD | -520.893% |
| Invex Therapeutics Ltd | -1.64 Million AUD | -337.381% |
| NeuroScientific Biopharmaceuticals Limited | 324.21 Thousand AUD | 2314.91% |
| Island Pharmaceuticals Limited | -2.86 Million AUD | -150.704% |
| Biotron Limited | -3.43 Million AUD | -108.96% |
| Radiopharm Theranostics Limited | -47.94 Million AUD | 85.024% |
| Tissue Repair Ltd | -4.13 Million AUD | -73.533% |
| AnteoTech Limited | -8.88 Million AUD | 19.138% |
| Hexima Limited | -933.87 Thousand AUD | -668.944% |
| Paradigm Biopharmaceuticals Limited | -58.65 Million AUD | 87.757% |
| Recce Pharmaceuticals Ltd | -17.66 Million AUD | 59.342% |
| Avecho Biotechnology Limited | -3.43 Million AUD | -108.958% |
| Actinogen Medical Limited | -13.04 Million AUD | 44.949% |
| Immuron Limited | -6.93 Million AUD | -3.517% |
| Argenica Therapeutics Limited | -5.47 Million AUD | -31.052% |